Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ＡＴＰ放出の効果の強力化
Document Type and Number:
Japanese Patent JP2021502980
Kind Code:
A
Abstract:
本願発明は、癌の処置において可溶性ヒトＣＤ３９の酵素活性を阻害する化合物を使用して、腫瘍細胞からのＡＴＰの細胞外放出を誘導する及び／又は腫瘍細胞の死を誘導する薬剤又は処置の活性を強力化する方法に関する。

More Like This:
WO/2003/020875STAPHYLOCOCCI SURFACE-EXPOSED IMMUNOGENIC POLYPEPTIDES
JP7465833T cell recruitment polypeptide based on CD3 reactivity
JP2019052156THERAPEUTIC APPLICATIONS OF ACTIVATION OF HUMAN ANTIGEN-PRESENTING CELLS THROUGH DECTIN-1
Inventors:
Stephanie chantoux
Nicola Gourdan
Carine Patrell
Ivan Pero
Banjaman Rossi
Application Number:
JP2020526482A
Publication Date:
February 04, 2021
Filing Date:
November 15, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
INNATE PHARMA PHARMA S.A.
International Classes:
C07K16/28; A61K31/337; A61K33/243; A61K39/395; A61K45/00; A61K45/06; A61P1/00; A61P7/00; A61P11/00; A61P15/00; A61P35/00; A61P37/04; A61P43/00
Foreign References:
WO2017089334A12017-06-01
WO2016073845A12016-05-12
WO2017157948A12017-09-21
Other References:
SCIENCE (2011) VOL.334, NO.6062, P.1573-1577, SUPPORTING ONLINE MATERIAL, JPN6022029492, ISSN: 0005098542
CANCER IMMUNOL. RES. (2015) VOL.3, NO3, P.254-265, JPN6022029493, ISSN: 0005098543
Attorney, Agent or Firm:
Norihito Yamao
Kenji Tomita
Fumio Inai
Manami Sasakura



 
Previous Patent: ＢＣＭＡターゲティングキメラ抗原受容体、ＣＤ１９ターゲティングキメ...

Next Patent: ボツリヌス治療の副作用の処置